Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 574 clinical trials
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707)  

ul>

  • 0 views
  • 04 Apr, 2025
  • 1 location
  • Online study
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients  

  • The primary objective is to determine whether SAR408701 improves the overall survival (OS) when compared with docetaxel in participants with metastatic non-squamous NSCLC expressing CEACAM5 2+ in intensity in at least 50% of the tumor cell population and previously treated with standard-of-care platinum-based chemotherapy and an immune checkpoint inhibitor.
    • ul>

    …

    docetaxel
    non-squamous non-small cell lung cancer
    measurable disease
    platinum-based chemotherapy
    squamous non-small cell lung cancer
    • 0 views
    • 19 Feb, 2024
    • 55 locations
    A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

    Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during induction phase:-

    <ul>
  • Arm A: Tiragolumab plus atezolizumab and CE
  • Arm B: Placebo plus atezolizumab and CE
    • ul>

    Following the induction phase, participants will continue maintenance therapy with either atezolizumab …

    measurable disease
    extensive stage sclc
    etoposide
    solid tumour
    carboplatin
    • 0 views
    • 19 Feb, 2024
    • 147 locations
    Determination of the Optimal Treatment Target in Ulcerative Colitis

    Participants with active UC will be randomized in a 2:3:5 ratio to 1 of 3 groups, each with a different treatment target. Treatment targets will be defined as:

    <ul>
  • Group 1: corticosteroid-free symptomatic remission
  • Group 2: corticosteroid-free endoscopic + symptomatic remission
  • Group 3: corticosteroid-free histological + endoscopic …

    ulcerative colitis
    corticosteroids
    colitis
    hematochezia
    tuberculosis
    • 0 views
    • 19 Feb, 2024
    • 1 location
    Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (AIRLYMPUS)

  • The investigational treatment duration will be up to approximately 52 weeks.
  • The number of visits will be 18.
    • ul>

    • 0 views
    • 24 Nov, 2025
    • 51 locations
    A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

    ul>

    follicular lymphoma
    leukapheresis
    systemic therapy
    marginal zone lymphoma
    alkylating agents
    • 0 views
    • 19 Feb, 2024
    • 36 locations
    SAR439859 Plus Palbociclib as First Line Therapy for Patients With ER(+) HER2(-) Advanced Breast Cancer

    Primary Objective:

    To determine whether SAR439859 in combination with palbociclib improves progression free survival (PFS) when compared with letrozole in combination with palbociclib in participants with ER+, HER2- advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease.

    Secondary Objective:

    <ul>
  • To compare …

    solid tumors
    measurable disease
    advanced breast cancer
    her2/neu-negative breast cancer
    HER2
    • 0 views
    • 19 Feb, 2024
    • 5 locations
    Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

  • To compare the overall safety profile in the 2 treatment arms.
    • ul>

    fulvestrant
    estrogen receptor positive breast cancer
    endocrine therapy
    adenocarcinoma of the breast
    er-positive breast cancer
    • 0 views
    • 19 Feb, 2024
    • 131 locations
    Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis (FREVIVA)  

  • The number of scheduled visits will be up to 27 (including 3 follow-up visits) with a visit frequency of every month for the first 6 months and then every 3 months.
    • ul>

    • 0 views
    • 04 Mar, 2025
    • 59 locations
    A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients

  • To evaluate the effect of venglustat on the lens by ophthalmological examination (Stages 1 and 2).
    • ul>

    chronic kidney disease
    fatigue
    autosomal dominant
    tolvaptan
    polycystic kidney disease
    • 0 views
    • 19 Feb, 2024
    • 81 locations